Comparative Pharmacology
Head-to-head clinical analysis: PRIMACOR versus PRIMACOR IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRIMACOR versus PRIMACOR IN DEXTROSE 5 IN PLASTIC CONTAINER.
PRIMACOR vs PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-3 (PDE-3) inhibitor, increasing cAMP in cardiac and vascular smooth muscle, leading to positive inotropy and vasodilation.
Milrinone is a selective phosphodiesterase III (PDE3) inhibitor that increases intracellular cyclic adenosine monophosphate (cAMP) in cardiac and vascular smooth muscle, leading to positive inotropy and vasodilation.
IV bolus: 0.75 mg/kg over 10-15 minutes, followed by continuous IV infusion of 5-10 mcg/kg/min. Maximum daily dose: 40 mg.
IV loading dose of 50 mcg/kg over 10 minutes, followed by continuous IV infusion of 0.375-0.75 mcg/kg/min; adjust based on hemodynamic response; maximum infusion rate 1.13 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged to 8-12 hours in severe renal impairment.
Terminal elimination half-life: 2.5-3.5 hours; prolonged in heart failure (up to 4.5-5 hours) and renal impairment
Primarily renal (60-70% unchanged), with minor biliary/fecal (15-20%).
Renal: 50-70% unchanged; biliary/fecal: minimal
Category C
Category C
Inotrope (Phosphodiesterase inhibitor)
Inotrope (Phosphodiesterase inhibitor)